Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) shot up 6.8% during trading on Tuesday . The stock traded as high as $0.49 and last traded at $0.47. 1,354,800 shares were traded during trading, a decline of 9% from the average session volume of 1,493,320 shares. The stock had previously closed at $0.44.

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) last issued its earnings results on Tuesday, August 14th. The specialty pharmaceutical company reported $0.05 earnings per share (EPS) for the quarter.

Institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers bought a new position in Ampio Pharmaceuticals in the 2nd quarter valued at about $154,000. Valeo Financial Advisors LLC bought a new position in Ampio Pharmaceuticals in the 2nd quarter valued at about $155,000. Courier Capital LLC raised its holdings in Ampio Pharmaceuticals by 2,032.7% in the 3rd quarter. Courier Capital LLC now owns 304,973 shares of the specialty pharmaceutical company’s stock valued at $155,000 after acquiring an additional 290,673 shares during the period. A.R.T. Advisors LLC bought a new position in Ampio Pharmaceuticals in the 1st quarter valued at about $258,000. Finally, Element Capital Management LLC bought a new position in Ampio Pharmaceuticals in the 1st quarter valued at about $290,000.

About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability.

Recommended Story: How to Invest in an Index Fund

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.